AIM ImmunoTech Inc presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship.
AIM ImmunoTech Inc presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship.